Galena Biopharma, Inc.

Vifor Pharma Group is hopeful that its hyperkalemia therapy Veltassa, which enjoyed strong sales growth in 2019, will be able to fend off competition from AstraZeneca PLC 's rival treatment Lokelma.

Galenica 's Verfora consumer health division took top spot in the Swiss market for the first time last year, propelled by strong growth from its leading OTC brands. “Verfora became the number-one comp

After announcing its first full-year results as a standalone company, Vifor Pharma Group has laid out ambitious growth plans to more than double sales by 2020, driven by two potential blockbusters –

The Swiss antibiotics-to-immuno-oncology drug discovery company, Polyphor Ltd. , is planning an IPO and listing on the SIX Stock Exchange in Switzerland, an increasingly popular destination in Europe